ondasdechoque.org
PT-BR

Shockwaves added to early zoster care · Comparison study · 2026

Does adding shockwave to early shingles care ease the pain?

In this hospital study, people who added six shockwave sessions to usual shingles care saw pain fall from about 7 to about 1 out of 10 by three months after leaving hospital, against under 3 with usual care alone. Fewer developed lasting nerve pain: 2 of 41 against 13 of 41.

Possible early help for shingles pain
adults aged 50–80 with new shingles pain
82
sessions over 3 weeks
6
months of follow-up after leaving hospital
3

Good to know: Not randomised: doctors and patients chose who had shockwave. Everyone also got antiviral and pain medicines.

Cheng F, Yu Y, Zhang J Medicine (Baltimore), 2026 · Read the paper ↗

How this study worked

Shockwave + usual care41 peopleUsual care alone41 people
Groups were compared, but people were not assigned to them by lot. Each dot is one person.

Conceptual animation: a focused front converges, then spreads. Not to scale. Tap the field to send a pulse.

What happened

Shingles pain

0–10 pain scale · start and three months after leaving hospital

Start3 months after leaving hospital

Pain fell in both groups: from about 7 to about 1 with added shockwave, and from about 7 to under 3 with usual care alone.
Show the numbers
GroupPeopleStart3 months after leaving hospital
Shockwave + usual care417.11.2
Usual care alone417.22.6

The treatment

Shockwave + usual care

Shockwave, twice a week for 3 weeks

ShockwavesThe paper doesn’t say whether radial or focused
Sessions
6, two a week
Pulses
4,000 per session · to the muscles beside the spine
Strength
0.25mJ/mm² at 4–8 pulses a second, adjusted to comfort
Numbing
Not mentioned
Device
Dornier
Everyone also got
Antiviral, nerve-pain and anti-inflammatory medicines, plus posture and activity advice

Compared with: The same medicines and advice without shockwave

Settings are what each study used, not a prescription.

Who took part

82 adults aged 50–80 in hospital with shingles pain on the chest or lower back, all within a month of it starting; 41 also had shockwave.

Shockwave + usual care41 people
Usual care alone41 people

Side effects

The paper did not report on side effects.

All the numbers and the full appraisal

Every reported result

FROM THE FULL PAPER

The results, in numbers.

Adults 50–80 years with thoracic/lumbar segmental zoster pain lasting≤1 month, admitted May 2023–June 2024. MRI abnormalities were found in 74/82. Uncontrolled disease, anticoagulation, spinal infection/tumor, fracture and incomplete records were excluded.

Usual care plus ESWT41enrolled

Source reports this participant group.

Usual care41enrolled

Source reports this participant group.

Pain intensity3 reported outcomes
01
One week; source inconsistently anchors this to treatment initiation or treatment

Pain intensity

NRS points

Pain intensity · One week; source inconsistently anchors this to treatment initiation or treatment · means
GroupnBaselineFollow-up
Usual care plus ESWT417.1 (SD 1)4.9 (SD 0.8)
Usual care417.2 (SD 1.1)5.3 (SD 1)

Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.

REPORTED COMPARISON TESTp = 0.067

ESWT plus usual care versus usual care

Source-reported between-group test

Reported group means; within-group change is not a between-group treatment effect.

Analysis details and source

Mean ± SD as printed. No effect or confidence interval reconstructed.

02
One month after discharge

Pain intensity

NRS points

Pain intensity · One month after discharge · means
GroupnBaselineFollow-up
Usual care plus ESWT417.1 (SD 1)2.4 (SD 0.9)
Usual care417.2 (SD 1.1)3.3 (SD 1.1)

Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.

REPORTED COMPARISON TESTp = 0.004

ESWT plus usual care versus usual care

Source-reported between-group test

Reported group means; within-group change is not a between-group treatment effect.

Analysis details and source

Mean ± SD as printed. No effect or confidence interval reconstructed.

03
Three months after discharge

Pain intensity

NRS points

Pain intensity · Three months after discharge · means
GroupnBaselineFollow-up
Usual care plus ESWT417.1 (SD 1)1.2 (SD 0.6)
Usual care417.2 (SD 1.1)2.6 (SD 1)

Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.

REPORTED COMPARISON TESTp <0.001

ESWT plus usual care versus usual care

Source-reported between-group test

Reported group means; within-group change is not a between-group treatment effect.

Analysis details and source

Mean ± SD as printed. No effect or confidence interval reconstructed.

Sleep quality3 reported outcomes
04
One week; source inconsistently anchors this to treatment initiation or treatment

Sleep quality

PSQI points

Sleep quality · One week; source inconsistently anchors this to treatment initiation or treatment · means
GroupnBaselineFollow-up
Usual care plus ESWT4112.3 (SD 2.1)8.5 (SD 1.9)
Usual care4112.6 (SD 2.4)9.6 (SD 2)

Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.

REPORTED COMPARISON TESTp = 0.018

ESWT plus usual care versus usual care

Source-reported between-group test

Reported group means; within-group change is not a between-group treatment effect.

Analysis details and source

Mean ± SD as printed. No effect or confidence interval reconstructed.

05
One month after discharge

Sleep quality

PSQI points

Sleep quality · One month after discharge · means
GroupnBaselineFollow-up
Usual care plus ESWT4112.3 (SD 2.1)5.2 (SD 1.6)
Usual care4112.6 (SD 2.4)7.3 (SD 2.1)

Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.

REPORTED COMPARISON TESTp <0.001

ESWT plus usual care versus usual care

Source-reported between-group test

Reported group means; within-group change is not a between-group treatment effect.

Analysis details and source

Mean ± SD as printed. No effect or confidence interval reconstructed.

06
Three months after discharge

Sleep quality

PSQI points

Sleep quality · Three months after discharge · means
GroupnBaselineFollow-up
Usual care plus ESWT4112.3 (SD 2.1)3.6 (SD 1.3)
Usual care4112.6 (SD 2.4)6.1 (SD 2)

Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.

REPORTED COMPARISON TESTp <0.001

ESWT plus usual care versus usual care

Source-reported between-group test

Reported group means; within-group change is not a between-group treatment effect.

Analysis details and source

Mean ± SD as printed. No effect or confidence interval reconstructed.

Spinal imaging score3 reported outcomes
07
One week; source inconsistently anchors this to treatment initiation or treatment

Spinal imaging score

SMIS points

Spinal imaging score · One week; source inconsistently anchors this to treatment initiation or treatment · means
GroupnBaselineFollow-up
Usual care plus ESWT4154.6 (SD 7.3)51 (SD 6.1)
Usual care4153.9 (SD 6.8)52.2 (SD 6.5)

Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.

REPORTED COMPARISON TESTp = 0.327

ESWT plus usual care versus usual care

Source-reported between-group test

Reported group means; within-group change is not a between-group treatment effect.

Analysis details and source

Mean ± SD as printed. No effect or confidence interval reconstructed.

08
One month after discharge

Spinal imaging score

SMIS points

Spinal imaging score · One month after discharge · means
GroupnBaselineFollow-up
Usual care plus ESWT4154.6 (SD 7.3)45.8 (SD 5.4)
Usual care4153.9 (SD 6.8)50.3 (SD 6.2)

Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.

REPORTED COMPARISON TESTp = 0.002

ESWT plus usual care versus usual care

Source-reported between-group test

Reported group means; within-group change is not a between-group treatment effect.

Analysis details and source

Mean ± SD as printed. No effect or confidence interval reconstructed.

09
Three months after discharge

Spinal imaging score

SMIS points

Spinal imaging score · Three months after discharge · means
GroupnBaselineFollow-up
Usual care plus ESWT4154.6 (SD 7.3)40.2 (SD 5)
Usual care4153.9 (SD 6.8)47.1 (SD 5.9)

Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.

REPORTED COMPARISON TESTp <0.001

ESWT plus usual care versus usual care

Source-reported between-group test

Reported group means; within-group change is not a between-group treatment effect.

Analysis details and source

Mean ± SD as printed. No effect or confidence interval reconstructed.

Postherpetic neuralgia1 reported outcome
10
Three months

Postherpetic neuralgia

people

Usual care plus ESWT2 / 41
Usual care13 / 41

Source-reported unadjusted counts; allocation was not random.

Analysis details and source

Descriptive source-reported counts; no effect estimate reconstructed.

NRS≤31 reported outcome
11
Three months

NRS≤3

people

Usual care plus ESWT38 / 41
Usual care24 / 41

Source-reported unadjusted counts; allocation was not random.

Analysis details and source

Descriptive source-reported counts; no effect estimate reconstructed.

PSQI≤51 reported outcome
12
Three months

PSQI≤5

people

Usual care plus ESWT34 / 41
Usual care18 / 41

Source-reported unadjusted counts; allocation was not random.

Analysis details and source

Descriptive source-reported counts; no effect estimate reconstructed.

SMIS improvement≥20%1 reported outcome
13
Three months

SMIS improvement≥20%

people

Usual care plus ESWT34 / 41
Usual care17 / 41

Source-reported unadjusted counts; allocation was not random.

Analysis details and source

Descriptive source-reported counts; no effect estimate reconstructed.

Early null comparisons1 reported outcome
14
As reported in the article

Early null comparisons

Qualitative finding

At 3 months ESWT/control NRS 1.2±0.6/2.6±1.0, PSQI 3.6±1.3/6.1±2.0, SMIS 40.2±5.0/47.1±5.9; reported p<.001. PHN occurred in 2/41 versus 13/41. Week 1 NRS and SMIS comparisons were nonsignificant (p=.067/.327), despite later differences. These are unadjusted associations, not prevention proof.

Analysis details and source

Qualitative extraction preserves the source scope.

How treatment was delivered
Regimen

Dornier electromagnetic shockwave device applied to the paraspinal muscles adjacent to the affected segments, 4,000 pulses/session, 0.25 mJ/mm², 4–8 Hz, pressure reported 1–5 MPa; twice weekly for 3 weeks, 6 sessions. Settings adjusted to tolerance/location.

Shared treatment

Both groups received antivirals, neuropathic analgesics such as pregabalin/amitriptyline, NSAIDs, supportive care and individualized postural/activity advice. Actual medication doses and adherence were not controlled in the comparison.

HARMS & TOLERABILITY

The article reports no data on treatment adverse events or side effects. PHN is a disease outcome, not an ESWT safety event.

LIMITS OF THE ANALYSIS

Selection/confounding acknowledged; three-month follow-up, small sample and no adjusted analysis. SMIS called validated but scoring items and reliability coefficients are not supplied. Several reported p values warrant checking against means/SD/n. Government/Hebei funding and no conflicts declared. A correction changes institutional affiliation from Technology to Engineering; ethics text still uses Technology.

Findings checked against the full source by a separate automated reviewer.

Limitations noted by the reviewers

  • Selection/confounding acknowledged; three-month follow-up, small sample and no adjusted analysis. SMIS called validated but scoring items and reliability coefficients are not supplied. Several reported p values warrant checking against means/SD/n. Government/Hebei funding and no conflicts declared. A correction changes institutional affiliation from Technology to Engineering; ethics text still uses Technology.
Research review

Source-linked critical reading

nonrandom comparative

Reading depthMaterial consulted
Technical source record

Complete local PDF text read, including all article body sections, tables, figure captions, discussion, disclosures and references. The article lists no supplementary material.

Review statusAI-assisted draft · independent automated checkThis automated check comes before the editor’s clinical review.
Study design

Single-centre retrospective comparison of 82 hospitalized patients,41 receiving usual care and 41 usual care plus ESWT. Treatment depended on physician judgment, patient preference and device availability; no randomization or confounder-adjusted effect was reported.

Participants and setting

Adults 50–80 years with thoracic/lumbar segmental zoster pain lasting≤1 month, admitted May 2023–June 2024. MRI abnormalities were found in 74/82. Uncontrolled disease, anticoagulation, spinal infection/tumor, fracture and incomplete records were excluded.

Treatment

Dornier electromagnetic shockwave device applied to the paraspinal muscles adjacent to the affected segments, 4,000 pulses/session, 0.25 mJ/mm², 4–8 Hz, pressure reported 1–5 MPa; twice weekly for 3 weeks, 6 sessions. Settings adjusted to tolerance/location.

Comparison

Both groups received antivirals, neuropathic analgesics such as pregabalin/amitriptyline, NSAIDs, supportive care and individualized postural/activity advice. Actual medication doses and adherence were not controlled in the comparison.

Outcomes and timing

NRS, PSQI and the 20-item 0–100 spinal imaging score SMIS were assessed at 48 hours after admission, one week, and one/three months after discharge. The one-week anchor is inconsistent: Methods says after treatment, Results after initiation, although the course lasts three weeks. PHN beyond 90 days from onset conflicts with the introduction’s rash-resolution reference.

What the results show

At 3 months ESWT/control NRS 1.2±0.6/2.6±1.0, PSQI 3.6±1.3/6.1±2.0, SMIS 40.2±5.0/47.1±5.9; reported p<.001. PHN occurred in 2/41 versus 13/41. Week 1 NRS and SMIS comparisons were nonsignificant (p=.067/.327), despite later differences. These are unadjusted associations, not prevention proof.

Harms

The article reports no data on treatment adverse events or side effects. PHN is a disease outcome, not an ESWT safety event.

Limits and disclosures

Selection/confounding acknowledged; three-month follow-up, small sample and no adjusted analysis. SMIS called validated but scoring items and reliability coefficients are not supplied. Several reported p values warrant checking against means/SD/n. Government/Hebei funding and no conflicts declared. A correction changes institutional affiliation from Technology to Engineering; ethics text still uses Technology.

Application to care

Limited to early segmental zoster in selected inpatients. It cannot justify replacing antiviral/neuropathic care or treating imaging change as a demonstrated mechanism of neural recovery.

What remains to be tested

Prospective randomization, standardized medicines, transparent SMIS validation, prespecified PHN timing and 6–12 month follow-up would test the hypothesis.

THE ORIGINAL SOURCE

Read the original article.

Extracorporeal shockwave therapy for zoster-associated pain: A retrospective analysis based on spinal musculoskeletal imbalance

Cheng F, Yu Y, Zhang J. · Medicine (Baltimore) · 2026

Open the publication record or available full-text files.

Checked against the full paper · Clinical review: Dr. Marcus Yu Bin Pai, · How we review →